Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Gilead Files Trodelvy for Triple-Negative Breast Cancer in Japan
Gilead Sciences said on January 30 that it has submitted a new drug application in Japan for sacituzumab govitecan for the treatment of hormone receptor-negative, HER2 negative breast cancer, commonly called triple-negative breast cancer.The drug, approved as Trodelvy in the US…
To read the full story
Related Article
- Trodelvy Nears Japan Approval as It Sails through Panel Review
September 13, 2024
- Trodelvy Up for Japan Panel Review on Sept. 12, Meiji COVID Jab on Agenda Too
September 6, 2024
- Gilead Japan Ramping Up Sales Force with Trodelvy Now under Review
February 20, 2024
- Trodelvy Launch on Horizon, Gilead Japan to Hire Oncology Reps from Early 2024
July 26, 2023
BUSINESS
- Sanofi Eyes Double-Digit Annual Growth for Japan Vaccine Business: Exec
May 20, 2026
- Takeda Hit with Massive Damages Verdict in US Amitiza Antitrust Case
May 20, 2026
- Top Generic Makers Grow Sales on Higher Output, Shipment Recovery
May 20, 2026
- Tapinarof Cream Logs Positive Data in Infant Atopic Dermatitis: Shionogi
May 20, 2026
- Bayer Files FXIa Inhibitor Asundexian in Japan
May 20, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…